glp-1 agonist consultation process Agonists : Cost , Info, Risks, Reviews Can one drug do it
Description
JAMA Cardiol (2020) 5(10):118290
Tirzepatide (Zepbound/Mounjaro) is a dual agonist that activates two hormone receptors: GLP-1 and GIP
At a 50% penetration rate, a 68-week course of Mounjaro would (in this ideal, nave assumption) bring the obesity rate to the lowest level its been since 1981
Funding The work was funded exclusively by Novo Nordisk A/S
Alternatively, others like dulaglutide (Trulicity) are administered once a week
The basal insulin/DPP-4 inhibitor combination is a practical and a less complicated treatment option without the need for multiple injections during the day, less need for glucose self-measurements and dose adjustments for insulin (7074)
